| Name | Market Cap | Current Price | P/E Ratio | Revenue Growth 1Y | Net Margin | ROE | FCF Yield | Debt/Equity |
|---|---|---|---|---|---|---|---|---|
| BIAFbioAffinity Technologies, Inc. | 6.39M | 1.42 | -0.06 | 269.75% | -217.5% | -165.57% | 0.58 | |
| VNRXVolitionRx Limited | 35.61M | 0.29 | -0.94 | 59.1% | -15.54% | |||
| BDSXBiodesix, Inc. | 66.27M | 8.33 | -1.26 | 45.3% | -49.31% | -337.3% | 2.97 | |
| GRALGRAIL, Inc. | 3.8B | 97.44 | -1.53 | 34.9% | -286.43% | -18.14% | 0.03 | |
| GHGuardant Health, Inc. | 14.54B | 111.98 | -31.46 | 31.04% | -44.18% | -45.84% | ||
| ADVBAdvanced Biomed Inc. Common Stock | 6.86M | 0.32 | -67.45 | -135.32% | -77.48% | 0.00 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Sales/Revenue | 20.43M | 24.55M | 45.56M | 54.51M | 38.21M | 49.09M | 71.32M |
| Revenue Growth % | - | 0.2% | 0.86% | 0.2% | -0.3% | 0.28% | 0.45% |
| Cost of Goods Sold | 4.41M | 6.07M | 22M | 30.52M | 14.15M | 13.01M | 15.57M |
| COGS % of Revenue | 0.22% | 0.25% | 0.48% | 0.56% | 0.37% | 0.27% | 0.22% |
| Gross Profit | 16.03M | 18.48M | 23.56M | 23.99M | 24.06M | 36.08M | 55.75M |
| Gross Margin % | 0.78% | 0.75% | 0.52% | 0.44% | 0.63% | 0.73% | 0.78% |
| Gross Profit Growth % | - | 0.15% | 0.27% | 0.02% | 0% | 0.5% | 0.55% |
| Operating Expenses | 34.09M | 45.22M | 46.49M | 64.93M | 74.64M | 77.42M | 90.25M |
| OpEx % of Revenue | 1.67% | 1.84% | 1.02% | 1.19% | 1.95% | 1.58% | 1.27% |
| Selling, General & Admin | 25.9M | 30.64M | 34.86M | 50.52M | 61.46M | 67.39M | 80.45M |
| SG&A % of Revenue | 1.27% | 1.25% | 0.77% | 0.93% | 1.61% | 1.37% | 1.13% |
| Research & Development | 8.19M | 10.47M | 10.82M | 12.79M | 13.1M | 9.99M | 9.56M |
| R&D % of Revenue | 0.4% | 0.43% | 0.24% | 0.23% | 0.34% | 0.2% | 0.13% |
| Other Operating Expenses | 0 | 4.11M | 818K | 1.62M | 81K | 44K | 238K |
| Operating Income | -23.46M | -26.74M | -22.93M | -40.94M | -50.59M | -41.34M | -34.5M |
| Operating Margin % | -1.15% | -1.09% | -0.5% | -0.75% | -1.32% | -0.84% | -0.48% |
| Operating Income Growth % | - | -0.14% | 0.14% | -0.79% | -0.24% | 0.18% | 0.17% |
| EBITDA | -21.72M | -23.95M | -20.03M | -37.76M | -44.74M | -35.84M | -29.04M |
| EBITDA Margin % | -1.06% | -0.98% | -0.44% | -0.69% | -1.17% | -0.73% | -0.41% |
| EBITDA Growth % | - | -0.1% | 0.16% | -0.89% | -0.18% | 0.2% | 0.19% |
| D&A (Non-Cash Add-back) | 1.74M | 2.79M | 2.9M | 3.18M | 5.84M | 5.51M | 5.46M |
| EBIT | -23.25M | -27.72M | -23.75M | -38.65M | -57.38M | -42.61M | -34.67M |
| Net Interest Income | -2.89M | -2.95M | -7.6M | -4.51M | -8.07M | -9.54M | -8.26M |
| Interest Income | 24K | 55K | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 2.92M | 3.01M | 7.6M | 4.51M | 8.07M | 9.54M | 8.26M |
| Other Income/Expense | -2.71M | -3.98M | -8.42M | -2.22M | -14.86M | -10.8M | -8.43M |
| Pretax Income | -26.17M | -30.73M | -31.35M | -43.16M | -65.45M | -52.15M | -42.93M |
| Pretax Margin % | -1.28% | -1.25% | -0.69% | -0.79% | -1.71% | -1.06% | -0.6% |
| Income Tax | 211K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | 1% | 1% | 1% | 1% | 1% | 1% | 1% |
| Net Income | -26.17M | -30.73M | -31.35M | -43.16M | -65.45M | -52.15M | -42.93M |
| Net Margin % | -1.28% | -1.25% | -0.69% | -0.79% | -1.71% | -1.06% | -0.6% |
| Net Income Growth % | - | -0.17% | -0.02% | -0.38% | -0.52% | 0.2% | 0.18% |
| Net Income (Continuing) | -26.17M | -30.73M | -31.35M | -43.16M | -65.45M | -52.15M | -42.93M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -19.80 | -0.67 | -6.48 | -31.60 | -31.00 | -12.80 | -6.60 |
| EPS Growth % | - | 0.97% | -8.67% | -3.88% | 0.02% | 0.59% | 0.48% |
| EPS (Basic) | -19.80 | -0.67 | -6.48 | -31.60 | -31.00 | -12.80 | -6.60 |
| Diluted Shares Outstanding | 1.33M | 45.71M | 4.84M | 1.37M | 2.11M | 4.11M | 6.48M |
| Basic Shares Outstanding | 1.33M | 45.71M | 4.84M | 1.37M | 2.11M | 4.11M | 6.48M |
| Dividend Payout Ratio | - | - | - | - | - | - | - |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Total Current Assets | 9.91M | 12.7M | 86.14M | 43.61M | 53.33M | 39.68M | 39.48M |
| Cash & Short-Term Investments | 5.91M | 5.29M | 62.13M | 32.71M | 43.09M | 26.28M | 26.25M |
| Cash Only | 5.91M | 5.29M | 62.13M | 32.71M | 43.09M | 26.28M | 26.25M |
| Short-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accounts Receivable | 1.89M | 5.29M | 15.3M | 3.66M | 5.07M | 7.68M | 8.6M |
| Days Sales Outstanding | 33.8 | 78.67 | 122.61 | 24.48 | 48.38 | 57.1 | 44.03 |
| Inventory | 700K | 800K | 3.2M | 2.9M | 1.4M | 1.4M | 0 |
| Days Inventory Outstanding | 57.99 | 48.07 | 53.1 | 34.68 | 36.1 | 39.28 | - |
| Other Current Assets | 1.41M | 1.32M | 8.71M | 7.25M | 5.18M | 4.32M | 4.64M |
| Total Non-Current Assets | 29.14M | 28.93M | 34.93M | 32.48M | 39.57M | 59.41M | 57.76M |
| Property, Plant & Equipment | 1.39M | 2.12M | 3.18M | 4.18M | 8.82M | 29.61M | 29.59M |
| Fixed Asset Turnover | 14.72x | 11.58x | 14.34x | 13.04x | 4.33x | 1.66x | 2.41x |
| Goodwill | 10.8M | 11.63M | 15.03M | 15.03M | 15.03M | 15.03M | 15.03M |
| Intangible Assets | 16.85M | 15.09M | 13.26M | 11.62M | 9.8M | 7.91M | 5.87M |
| Long-Term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Current Assets | 99K | 90K | 3.46M | 1.66M | 5.92M | 6.86M | 7.26M |
| Total Assets | 39.06M | 41.63M | 121.07M | 76.1M | 92.91M | 99.1M | 97.24M |
| Asset Turnover | 0.52x | 0.59x | 0.38x | 0.72x | 0.41x | 0.50x | 0.73x |
| Asset Growth % | - | 0.07% | 1.91% | -0.37% | 0.22% | 0.07% | -0.02% |
| Total Current Liabilities | 4.47M | 22.6M | 32.13M | 28.96M | 22.84M | 33.42M | 14.32M |
| Accounts Payable | 886K | 1.72M | 8.96M | 1.66M | 1.69M | 2.93M | 2.19M |
| Days Payables Outstanding | 73.4 | 103.18 | 148.73 | 19.88 | 43.45 | 82.17 | 51.42 |
| Short-Term Debt | 0 | 12.16M | 11.84M | 19K | 49K | 51K | 21K |
| Deferred Revenue (Current) | 492K | 1000K | 1000K | 1000K | 962K | 324K | 678K |
| Other Current Liabilities | 2.09M | 6.28M | 3.81M | 21.4M | 15.05M | 26M | 792K |
| Current Ratio | 2.22x | 0.56x | 2.68x | 1.51x | 2.34x | 1.19x | 2.76x |
| Quick Ratio | 2.06x | 0.53x | 2.58x | 1.41x | 2.27x | 1.15x | 2.76x |
| Cash Conversion Cycle | 18.39 | 23.57 | 26.98 | 39.29 | 41.03 | 14.2 | - |
| Total Non-Current Liabilities | 232.62M | 247.57M | 47.78M | 27.41M | 49.46M | 61.1M | 62.05M |
| Long-Term Debt | 23.1M | 23.81M | 15.93M | 9.99M | 25M | 35.23M | 36.41M |
| Capital Lease Obligations | 0 | 0 | 0 | 0 | 5.25M | 25.16M | 24.83M |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | -400K | 0 | 0 |
| Other Non-Current Liabilities | 209.52M | 223.76M | 31.85M | 17.42M | 19.2M | 712K | 815K |
| Total Liabilities | 237.09M | 270.17M | 79.9M | 56.37M | 72.3M | 94.52M | 76.37M |
| Total Debt | 23.1M | 35.97M | 27.77M | 10.01M | 31.85M | 60.69M | 61.98M |
| Net Debt | 17.18M | 30.68M | -34.36M | -22.7M | -11.24M | 34.41M | 35.73M |
| Debt / Equity | - | - | 0.67x | 0.51x | 1.55x | 13.25x | 2.97x |
| Debt / EBITDA | - | - | - | - | - | - | - |
| Net Debt / EBITDA | - | - | - | - | - | - | - |
| Interest Coverage | -8.05x | -8.89x | -3.02x | -9.08x | -6.27x | -4.34x | -4.18x |
| Total Equity | -198.03M | -228.54M | 41.17M | 19.73M | 20.61M | 4.58M | 20.88M |
| Equity Growth % | - | -0.15% | 1.18% | -0.52% | 0.04% | -0.78% | 3.56% |
| Book Value per Share | -149.22 | -5.00 | 8.51 | 14.42 | 9.79 | 1.12 | 3.22 |
| Total Shareholders' Equity | -198.03M | -228.54M | 41.17M | 19.73M | 20.61M | 4.58M | 20.88M |
| Common Stock | 1K | 1K | 27K | 31K | 78K | 96K | 145K |
| Retained Earnings | -200.14M | -230.86M | -258.81M | -301.97M | -367.42M | -419.57M | -462.5M |
| Treasury Stock | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accumulated OCI | -5.57M | -193.96M | -121.07M | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | |
|---|---|---|---|---|---|---|---|
| Cash from Operations | -17.68M | -21.73M | -21.37M | -28.22M | -44.97M | -22.87M | -48.65M |
| Operating CF Margin % | -0.87% | -0.88% | -0.47% | -0.52% | -1.18% | -0.47% | -0.68% |
| Operating CF Growth % | - | -0.23% | 0.02% | -0.32% | -0.59% | 0.49% | -1.13% |
| Net Income | -26.17M | -30.73M | -31.35M | -43.16M | -65.45M | -52.15M | -42.93M |
| Depreciation & Amortization | 1.74M | 2.79M | 2.9M | 3.18M | 5.84M | 5.51M | 5.46M |
| Stock-Based Compensation | 142K | 0 | 3.71M | 4.94M | 5.96M | 5.37M | 6.64M |
| Deferred Taxes | 47K | 0 | 1.6M | -2.1M | 0 | 0 | 0 |
| Other Non-Cash Items | 6.31M | 7.85M | 6.58M | 4.33M | 13.01M | 7.09M | 3.86M |
| Working Capital Changes | 253K | -1.65M | -4.8M | 4.59M | -4.34M | 11.3M | -21.67M |
| Change in Receivables | -146K | -3.65M | -10.31M | 11.45M | -1.5M | -4.72M | -1.81M |
| Change in Inventory | -389K | 0 | -11.65M | 7.42M | 906K | 166K | 22K |
| Change in Payables | 342K | 1.19M | 11.65M | -7.42M | -773K | 513K | 1.64M |
| Cash from Investing | -617K | -1.87M | -2.93M | -2.55M | -3.53M | -23.06M | -3.44M |
| Capital Expenditures | -617K | -1.42M | -2.18M | -2.55M | -3.53M | -22.92M | -3.23M |
| CapEx % of Revenue | 0.03% | 0.06% | 0.05% | 0.05% | 0.09% | 0.47% | 0.05% |
| Acquisitions | - | - | - | - | - | - | - |
| Investments | - | - | - | - | - | - | - |
| Other Investing | -119K | 0 | 0 | 0 | 0 | -143K | -210K |
| Cash from Financing | 19.03M | 22.97M | 81.13M | 1.26M | 58.88M | 29.13M | 52.05M |
| Debt Issued (Net) | - | - | - | - | - | - | - |
| Equity Issued (Net) | - | - | - | - | - | - | - |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | - | - | - | - | - | - | - |
| Other Financing | 23.18M | -116K | -6.91M | 269K | -17.15M | -8.95M | -3.52M |
| Net Change in Cash | - | - | - | - | - | - | - |
| Free Cash Flow | -18.29M | -23.04M | -23.54M | -30.77M | -48.51M | -45.93M | -51.88M |
| FCF Margin % | -0.9% | -0.94% | -0.52% | -0.56% | -1.27% | -0.94% | -0.73% |
| FCF Growth % | - | -0.26% | -0.02% | -0.31% | -0.58% | 0.05% | -0.13% |
| FCF per Share | -13.79 | -0.50 | -4.87 | -22.49 | -23.04 | -11.19 | -8.00 |
| FCF Conversion (FCF/Net Income) | 0.68x | 0.71x | 0.68x | 0.65x | 0.69x | 0.44x | 1.13x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|
| Return on Equity (ROE) | - | - | -76.16% | -141.75% | -324.53% | -414.09% | -337.3% |
| Return on Invested Capital (ROIC) | - | - | - | -1602.14% | -1186.56% | -128.25% | -54.13% |
| Gross Margin | 78.44% | 75.26% | 51.71% | 44.01% | 62.96% | 73.5% | 78.17% |
| Net Margin | -128.06% | -125.15% | -68.81% | -79.18% | -171.27% | -106.23% | -60.19% |
| Debt / Equity | - | - | 0.67x | 0.51x | 1.55x | 13.25x | 2.97x |
| Interest Coverage | -8.05x | -8.89x | -3.02x | -9.08x | -6.27x | -4.34x | -4.18x |
| FCF Conversion | 0.68x | 0.71x | 0.68x | 0.65x | 0.69x | 0.44x | 1.13x |
| Revenue Growth | - | 20.16% | 85.55% | 19.64% | -29.89% | 28.46% | 45.3% |
| 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|
| Development Services | - | - | - | - | 6.62M |
| Development Services Growth | - | - | - | - | - |
| Diagnostic Tests | - | 48.94M | 34.54M | 45.19M | - |
| Diagnostic Tests Growth | - | - | -29.42% | 30.85% | - |
| Service | - | 5.57M | 3.67M | - | - |
| Service Growth | - | - | -34.03% | - | - |
| C O V I D19 Diagnostic Test Revenue | 28.3M | - | - | - | - |
| C O V I D19 Diagnostic Test Revenue Growth | - | - | - | - | - |
| Lung Diagnostic Revenue | 12.6M | - | - | - | - |
| Lung Diagnostic Revenue Growth | - | - | - | - | - |
Biodesix, Inc. (BDSX) reported $80.2M in revenue for fiscal year 2024. This represents a 292% increase from $20.4M in 2018.
Biodesix, Inc. (BDSX) grew revenue by 45.3% over the past year. This is strong growth.
Biodesix, Inc. (BDSX) reported a net loss of $39.5M for fiscal year 2024.
Biodesix, Inc. (BDSX) has a return on equity (ROE) of -337.3%. Negative ROE indicates the company is unprofitable.
Biodesix, Inc. (BDSX) had negative free cash flow of $29.3M in fiscal year 2024, likely due to heavy capital investments.